Adaptin Bio (APTN) Change in Accured Expenses (2023 - 2026)

Adaptin Bio (APTN) has 4 years of Change in Accured Expenses data on file, last reported at $256901.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 1256.68% year-over-year to $256901.0; the trailing twelve-month figure through Mar 2026 stood at -$215480.0 (down 122.97% YoY), and the FY2025 full-year result was -$453445.0, down 153.26% from the prior year.
• Change in Accured Expenses rose to $256901.0 in Q1 2026, from -$467635.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $616507.0 in Q3 2024 to a low of -$547190.0 in Q2 2025.
• A 4-year average of $62632.5 and a median of $59656.5 in 2024 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses plunged 645.13% in 2025 and jumped 1256.68% in 2026, its largest moves.
• Tracing APTN's Change in Accured Expenses over 4 years: stood at -$28442.0 in 2023, then soared by 811.22% to $202286.0 in 2024, then tumbled by 331.18% to -$467635.0 in 2025, then jumped by 154.94% to $256901.0 in 2026.
• Business Quant data shows APTN's Change in Accured Expenses at $256901.0 in Q1 2026, -$467635.0 in Q4 2025, and $542444.0 in Q3 2025.